Bayer has expanded its collaboration with the Broad Institute of the Massachusetts Institute of Technology and Harvard University to include cardiovascular genomics. The project will seek to identify genes associated with cardiovascular disease and to create new therapies and diagnostics.

The organizations teamed up in 2013 to research the genetics of cancer. Centers for Disease Control and Prevention data indicates that cardiovascular disease accounts for about 25% of US deaths every year.